Compositions and methods for organoid generation and disease modeling

Patent metadata

Field	Value
Publication number	US-11760977-B2
Application number	US-201716301671-A
Country	US
Kind code	B2
Filing date	May 24, 2017
Priority date	May 25, 2016
Publication date	Sep 19, 2023
Grant date	Sep 19, 2023

Abstract

The invention features pancreatic islet and pancreatic organoids, and cell cultures and methods that are useful for the rapid and reliable generation of pancreatic islet and pancreatic islet organoids. The invention also features methods of treating pancreatic diseases and methods of identifying agents that are useful for treatment of pancreatic diseases, such as type 2 diabetes and pancreatic cancer, using the pancreatic islet and pancreatic organoids of the invention.

First claim

What is claimed is:

1. A method of treating a pancreatic disease in a subject, the method comprising administering a pancreatic islet organoid to the subject, wherein the pancreatic islet organoid comprises an induced pluripotent stem cell (iPSC)-derived beta-like cell, an iPSC-derived alpha cell and an iPSC-derived delta cell, and wherein the pancreatic islet organoid exhibits glucose-stimulated insulin secretion (GSIS), KCl-stimulated insulin secretion, GLP-stimulated insulin secretion, somatostatin secretion, and glucagon secretion.

2. The method of claim 1 , wherein the pancreatic islet organoid further comprises an adipose-derived stem cell and/or an endothelial cell.

3. The method of claim 2 , wherein the adipose-derived stem cell is a human adipose-derived stem cell (hADSC) and/or the endothelial cell is a human umbilical vein endothelial cell (HUVEC).

4. The method of claim 1 , wherein the pancreatic islet organoid expresses a beta cell transcription factor selected from the group consisting of: PDX1, MAFA, PAX4, PAX6, NEUROD1, NKX6-1, GATA6, and FOXA2.

5. The method of claim 1 , wherein the iPSC-derived beta-like cell, alpha cell and delta cell is a human cell.

6. The method of claim 1 , further wherein the pancreatic islet organoid is vascularized.

7. The method of claim 1 , wherein the pancreatic islet organoid is generated by culturing an iPSC-derived beta-like cell in a 3-dimensional matrix.

8. The method of claim 7 , wherein the 3-dimensional matrix comprises gellan gum and/or an extracellular matrix.

9. The method of claim 1 , wherein the pancreatic islet organoid is generated in vitro.

10. The method of claim 1 , wherein the pancreatic islet organoid expresses metabolic regulatory genes including ERRγ.

11. The method of claim 1 , wherein the subject is further administered an immunosuppressive agent.

12. The method of claim 1 , wherein the subject is human.

13. The method of claim 12 , wherein at least 100,000 pancreatic islet organoids are administered to the human subject.

14. The method of claim 12 , wherein the pancreatic disease is type 1 diabetes or type 2 diabetes.

15. The method of claim 14 , wherein the treatment ameliorates, reduces, and/or stabilizes the type I diabetes or type II diabetes in the subject.

16. The method of claim 1 , wherein the administering is by transplantation.

Assignees

• Salk Inst For Biological Studi

Inventors

• Evans Ronald
• Downes Michael
• Atkins Annette
• Yoshihara Eiji
• Yu Ruth

Classifications

• C12N5/0677 Primary

  Three-dimensional culture, tissue culture or organ culture; Encapsulated cells · CPC title

• G01N33/5088

  of vertebrates · CPC title

• C12N2501/117

  Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12) · CPC title

• C12N2501/16

  Activin; Inhibin; Mullerian inhibiting substance · CPC title

• C12N2501/385

  of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR] · CPC title